SCHEDULE 13D/A: HCW Biologics CEO Dr. Hing C. Wong Boosts Stake to 23.38% Through Strategic Debt-to-Equity Conversions

Dr. Hing C. Wong, Founder and CEO of HCW Biologics Inc., has significantly increased his beneficial ownership to 23.38% of the company's common stock by converting secured and unsecured notes into equity, a move aimed at strengthening the balance sheet.

Summary

• Dr. Hing C. Wong, Founder and Chief Executive Officer of HCW Biologics Inc., now beneficially owns 501,911 shares of Common Stock, representing approximately 23.38% of the company's outstanding shares.
• This ownership includes 103,192 shares held jointly with his spouse, Ms. Bee Yau Huang.
• The percentage is calculated based on 2,146,601 shares of common stock outstanding as of May 15, 2025, the closing date of the Company's follow-on public offering.
• On May 7, 2025, Dr. Wong converted his holdings of Secured Notes, purchasing 92,500 unregistered shares of Common Stock at $26.00 per share, for an aggregate amount of $2,405,000.
• On May 15, 2025, he converted his holdings of an unsecured promissory note, purchasing 8,054 shares of Common Stock at $7.45 per share, for an aggregate amount of $60,002.
• The total aggregate amount paid by Dr. Wong for his 501,911 shares is $19,969,141, all funded with personal funds.
• The stated purpose of these transactions is to clean up the balance sheet through the extinguishment of debt for equity.
• Dr. Wong is subject to a 180-day lock-up period from May 7, 2025, for shares received from the Secured Notes conversion.
• He is also subject to a 90-day lock-up period from May 15, 2025, for shares received from the unsecured promissory notes conversion.
• The Company also converted $6.6 million of Secured Notes into 253,083 unregistered shares and warrants, and $270,000 of unsecured promissory notes into 36,242 registered shares.

Sentiment

Score: 7

Explanation: The filing indicates a significant insider stake increase and a strategic move to clean up the balance sheet by converting debt to equity, which are generally positive signals for financial stability and management confidence, despite the associated dilution.

Positives

• The company's balance sheet is being strengthened through the extinguishment of debt for equity, reducing liabilities.
• The significant increase in beneficial ownership by the Founder and CEO, Dr. Hing C. Wong, signals strong insider confidence in the company's future.

Negatives

• The issuance of new shares through debt conversions and the follow-on public offering results in dilution for existing shareholders.
• The conversion price for Secured Notes ($26.00 per share) is significantly higher than the public offering price ($7.45 per unit), which could imply a premium paid by the CEO or a historical valuation difference.

Risks

• Potential for future dilution from the exercise of warrants issued in the May 7, 2025 conversion, which may be exercised to purchase up to $3.3 million of Common Stock at $26.00 per share.
• The lock-up periods restrict the reporting person's ability to sell shares, which could impact his personal liquidity for those specific holdings.

Future Outlook

The document indicates a strategic move to improve the company's financial health by cleaning up the balance sheet through the extinguishment of debt for equity, suggesting a positive outlook for financial stability.

Management Comments

• "Clean up the balance sheet through extinguishment of debt for equity."

Industry Context

This Schedule 13D filing primarily details an insider's ownership stake and corporate finance activities (debt-to-equity conversions and a public offering). While debt-to-equity conversions are a common strategy for companies, particularly in the biotech sector, to manage liabilities and raise capital, this document does not provide sufficient information to analyze broader industry trends or competitive positioning.

Related Party Transactions

• Dr. Hing C. Wong, the Founder and Chief Executive Officer of HCW Biologics Inc., converted his holdings of Secured Notes and an unsecured promissory note into shares of Common Stock.
• Dr. Wong entered into lock-up agreements with the Company regarding the shares received from these debt conversions.

Stakeholder Impact

• Shareholders: Existing shareholders experience dilution due to the issuance of new shares from debt conversions and the follow-on public offering. However, the balance sheet cleanup could improve the company's financial health, potentially benefiting shareholders long-term. The CEO's increased stake may signal confidence.
• Creditors: The conversion of debt to equity reduces the company's liabilities, which is positive for remaining creditors as it strengthens the balance sheet and reduces financial risk.

Next Steps

• Expiration of 180-day lock-up period for shares from Secured Notes conversion (approximately November 3, 2025).
• Expiration of 90-day lock-up period for shares from unsecured promissory notes conversion (approximately August 13, 2025).

Key Dates

Recommendation

Keywords

HCW Biologics, Hing C. Wong, Schedule 13D, beneficial ownership, debt conversion, equity conversion, common stock, SEC filing, biotech, corporate governance, balance sheet cleanup, follow-on offering, insider ownership